Literature DB >> 2271195

Ketamine induction and monoamine oxidase inhibitors.

D J Doyle1.   

Abstract

A 42-year-old woman taking tranylcypromine, a monoamine oxidase (MAO) inhibitor, was hypovolemic from a ruptured ectopic pregnancy and required an emergency laparotomy. Anesthetic induction with ketamine, an agent with sympathomimetic properties, was used because of her hypovolemia, despite theoretical concerns of precipitating an adrenergic crisis. The patient's hemodynamic course remained unchanged with induction and intubation, and with further fluid and blood administration, satisfactory hemodynamic conditions were obtained. This report is believed to be the first to describe the use of ketamine in a patient taking MAO inhibitors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2271195     DOI: 10.1016/0952-8180(90)90078-h

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  4 in total

1.  Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors:  William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

2.  Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.

Authors:  R B Katz; M Toprak; S T Wilkinson; G Sanacora; R Ostroff
Journal:  Gen Hosp Psychiatry       Date:  2018-05-22       Impact factor: 3.238

3.  Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.

Authors:  Vera M Ludwig; Cathrin Sauer; Allan H Young; James Rucker; Michael Bauer; Hannelore Findeis; Philipp Ritter
Journal:  CNS Drugs       Date:  2021-07-20       Impact factor: 5.749

4.  Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.

Authors:  Jolien K E Veraart; Sanne Y Smith-Apeldoorn; Iris M Bakker; Berber A E Visser; Jeanine Kamphuis; Robert A Schoevers; Daan J Touw
Journal:  Int J Neuropsychopharmacol       Date:  2021-10-23       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.